Inari Medical (NARI) Competitors $79.97 +0.04 (+0.05%) Closing price 02/18/2025 07:50 PM EasternExtended Trading$79.97 0.00 (0.00%) As of 02/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NARI vs. SOLV, SNN, PEN, GKOS, STVN, BLCO, INSP, NVST, PRCT, and IRTCShould you be buying Inari Medical stock or one of its competitors? The main competitors of Inari Medical include Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Glaukos (GKOS), Stevanato Group (STVN), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Envista (NVST), PROCEPT BioRobotics (PRCT), and iRhythm Technologies (IRTC). These companies are all part of the "medical equipment" industry. Inari Medical vs. Solventum Smith & Nephew Penumbra Glaukos Stevanato Group Bausch + Lomb Inspire Medical Systems Envista PROCEPT BioRobotics iRhythm Technologies Inari Medical (NASDAQ:NARI) and Solventum (NYSE:SOLV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation. Do analysts recommend NARI or SOLV? Inari Medical currently has a consensus price target of $68.00, indicating a potential downside of 14.97%. Solventum has a consensus price target of $68.29, indicating a potential downside of 6.40%. Given Solventum's higher possible upside, analysts plainly believe Solventum is more favorable than Inari Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inari Medical 0 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14Solventum 1 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is NARI or SOLV more profitable? Solventum has a net margin of 0.00% compared to Inari Medical's net margin of -13.68%. Solventum's return on equity of 0.00% beat Inari Medical's return on equity.Company Net Margins Return on Equity Return on Assets Inari Medical-13.68% -10.09% -6.60% Solventum N/A N/A N/A Does the MarketBeat Community favor NARI or SOLV? Inari Medical received 65 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 57.89% of users gave Inari Medical an outperform vote while only 5.56% of users gave Solventum an outperform vote. CompanyUnderperformOutperformInari MedicalOutperform Votes6657.89% Underperform Votes4842.11% SolventumOutperform Votes15.56%Underperform Votes1794.44% Do insiders and institutionals hold more shares of NARI or SOLV? 91.0% of Inari Medical shares are owned by institutional investors. 10.6% of Inari Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has stronger earnings & valuation, NARI or SOLV? Solventum has lower revenue, but higher earnings than Inari Medical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInari Medical$574.50M8.15-$1.64M-$1.35-59.24SolventumN/AN/AN/AN/AN/A Does the media prefer NARI or SOLV? In the previous week, Solventum had 3 more articles in the media than Inari Medical. MarketBeat recorded 11 mentions for Solventum and 8 mentions for Inari Medical. Solventum's average media sentiment score of 0.95 beat Inari Medical's score of 0.54 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inari Medical 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryInari Medical beats Solventum on 7 of the 13 factors compared between the two stocks. Get Inari Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for NARI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NARI vs. The Competition Export to ExcelMetricInari MedicalSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.68B$4.58B$5.80B$8.99BDividend YieldN/A39.91%4.78%3.85%P/E Ratio-59.2430.4926.3218.88Price / Sales8.1549.75452.0876.91Price / Cash906.9551.2344.0437.47Price / Book9.916.567.644.66Net Income-$1.64M$90.13M$3.18B$245.69M7 Day Performance0.05%-2.14%-1.66%-2.22%1 Month Performance0.59%-2.13%0.41%-1.95%1 Year Performance39.95%15.32%17.47%14.12% Inari Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NARIInari Medical1.6759 of 5 stars$79.97+0.1%$68.00-15.0%+37.6%$4.68B$574.50M-59.241,300High Trading VolumeSOLVSolventum0.399 of 5 stars$74.04-0.4%$68.29-7.8%N/A$12.79BN/A0.0022,000Upcoming EarningsSNNSmith & Nephew2.483 of 5 stars$25.72+0.0%N/A-9.8%$11.24B$5.55B0.0018,452Upcoming EarningsPENPenumbra4.459 of 5 stars$267.83-1.9%$261.36-2.4%+12.7%$10.28B$1.06B311.434,200Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGKOSGlaukos4.399 of 5 stars$153.06+4.6%$151.08-1.3%+71.4%$8.44B$314.71M-50.68780Earnings ReportAnalyst UpgradeInsider TradeNews CoverageGap DownSTVNStevanato Group1.236 of 5 stars€19.49+2.2%N/A-32.5%$5.90B$1.17B41.475,635Positive NewsBLCOBausch + Lomb3.7366 of 5 stars$16.44-1.2%$20.25+23.2%+9.1%$5.79B$4.15B-15.6513,300Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageINSPInspire Medical Systems4.8316 of 5 stars$184.73-1.3%$228.82+23.9%-7.0%$5.54B$624.80M172.651,011Insider TradeNVSTEnvista3.5382 of 5 stars$21.59+0.3%$20.21-6.4%-6.5%$3.71B$2.51B-3.3312,800PRCTPROCEPT BioRobotics3.2681 of 5 stars$67.61-2.4%$97.86+44.7%+33.5%$3.53B$199.84M-34.67430Positive NewsIRTCiRhythm Technologies1.0045 of 5 stars$112.11-0.1%$108.45-3.3%+0.2%$3.51B$492.68M-23.072,000Earnings ReportAnalyst ForecastNews CoverageGap Up Related Companies and Tools Related Companies Solventum Competitors Smith & Nephew Competitors Penumbra Competitors Glaukos Competitors Stevanato Group Competitors Bausch + Lomb Competitors Inspire Medical Systems Competitors Envista Competitors PROCEPT BioRobotics Competitors iRhythm Technologies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NARI) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inari Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inari Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
